Fludeoxyglucose F-18-PET in Planning Lung Cancer Radiation Therapy
Status:
Active, not recruiting
Trial end date:
2021-12-07
Target enrollment:
Participant gender:
Summary
This trial studies how well fludeoxyglucose F-18 - positron emission tomography (PET) works
in planning radiation therapy in participants with early non-small cell lung cancer, early
stage lung cancer, or cancer that has spread to lungs from other parts of the body. Using PET
in addition to the standard computed tomography to plan radiation therapy for cancer may help
doctors to maximize the dose to the cancer and minimize the dose to normal tissues.